Integration of the cancer-related pro-inflammatory response as a stratifying biomarker of survival benefit with sorafenib in hepatocellular carcinoma

Jessica Howell; David J. Pinato; Ramya Ramaswami; Tadaaki Arizumi; Cecilia Ferrari; Antonello Gibbin; Michela Emma Burlone; Giulia Guaschino; James R. Black; L. Sellers; Masatoshi Kudo; Mario Pirisi; Rajesh Sharma

Related publications

Article2017

Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib

Jessica Howell, David J. Pinato, Ramya Ramaswami, Tadaaki Arizumi, Carlotta Ferrari, Antonello Gibbin, Michela Emma Burlone, Giulia Guaschino, Pierluigi Toniutto, James R. Black, Laura Sellers, Masatoshi Kudo, Mario Pirisi, Rohini Sharma

Letter2017

Reply to: “Predictors of sorafenib benefit in patients with hepatocellular carcinoma”

Jordi Bruix, Ann‐Lii Cheng, Josep M. Llovet

Journal of Hepatology

Article2018

Predictor factor of survival in advanced hepatocellular carcinoma treated with sorafenib ∼a multicenter study∼

Chikara Ogawa, Masahiro Morita, Akina Omura, Mitsushige Shibatoge, Akemi Tsutsui, Tomonori Senoh, Takuya Nagano, Kouichi Takaguchi, Joji Tani, Asahiro Morishita, Hirohito Yoneyama, Tsutomu Masaki, Akio Moriya, Masaharu Ando, Akihiro Deguchi, Masatoshi Kudo

Article2014

Decreased Blood Flow after Sorafenib Administration Is an Imaging Biomarker to Predict Overall Survival in Patients with Advanced Hepatocellular Carcinoma

Tadaaki Arizumi, Kazuomi Ueshima, Hirokazu Chishina, Masashi Kono, Masahiro Takita, Satoshi Kitai, Tatsuo Inoue, Norihisa Yada, Satoru Hagiwara, Yasunori Minami, Toshiharu Sakurai, Naoshi Nishida, Masatoshi Kudo

Article2016

Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis

Satoshi Kitai, Masatoshi Kudo, Naoshi Nishida, Namiki Izumi, Michiie Sakamoto, Yutaka Matsuyama, Takafumi Ichida, Osamu Nakashima, Osamu Matsui, Yonson Ku, Norihiro Kokudo, Masatoshi Makuuchi